Table 2.
Demographics, clinical characteristics, and treatments of GC/GEJC/EAC patients, HER2 negative/ unknown, on first-line treatment
| Characteristic | Total | France | Germany | UK | US | Japan | China |
|---|---|---|---|---|---|---|---|
| n = 682 | n = 168 | n = 146 | n = 145 | n = 99 | n = 36 | n = 88 | |
| Age, years | |||||||
| Mean (SD) | 64.6 (10.0) | 65.0 (9.5) | 64.1 (8.9) | 66.3 (8.9) | 67.7 (8.6) | 69.8 (8.3) | 56.1 (11.4) |
| Median (IQR) | 66 (59–71) | 67 (60–71) | 65 (58–69) | 67 (63–72) | 68 (62–73) | 70 (63–77) | 57 (48–65) |
| Male (%) | 474 (69.5) | 127 (75.6) | 108 (74.0) | 95 (65.5) | 70 (70.7) | 23 (63.9) | 51 (58.0) |
| Confirmed diagnosis, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| GC | 415 (60.9) | 107 (63.7) | 90 (61.6) | 75 (51.7) | 41 (41.4) | 26 (72.2) | 76 (86.4) |
| GEJC | 192 (28.2) | 44 (26.2) | 43 (29.5) | 46 (31.7) | 43 (43.4) | 4 (11.1) | 12 (13.6) |
| EAC | 75 (11.0) | 17 (10.1) | 13 (8.9) | 24 (16.6) | 15 (15.2) | 6 (16.7) | 0 (0.0) |
| Lauren classification, n (%) | 599 | 148 | 144 | 126 | 68 | 31 | 82 |
| Diffuse | 231 (38.6) | 57 (38.5) | 52 (36.1) | 52 (41.3) | 26 (38.2) | 16 (51.6) | 28 (34.2) |
| Intestinal | 262 (43.7) | 73 (49.3) | 64 (44.4) | 47 (37.3) | 30 (44.1) | 13 (41.9) | 35 (42.7) |
| Mixed | 106 (17.7) | 18 (12.2) | 28 (19.4) | 27 (21.4) | 12 (17.7) | 2 (6.5) | 19 (23.2) |
| Comorbidities (> 5%), n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Diabetes | 107 (15.7) | 22 (13.1) | 24 (16.4) | 22 (15.3) | 22 (22.2) | 3 (8.3) | 14 (15.9) |
| Chronic pulmonary disease | 96 (14.1) | 24 (14.3) | 30 (20.6) | 22 (15.3) | 15 (15.2) | 0 (0.0) | 5 (5.7) |
| Anxiety | 82 (12.0) | 35 (20.8) | 8 (5.5) | 8 (5.5) | 19 (19.2) | 2 (5.6) | 10 (11.5) |
| Depression | 80 (11.7) | 15 (8.9) | 27 (18.5) | 12 (8.3) | 23 (23.2) | 0 (0.0) | 3 (3.4) |
| Peptic ulcer disease | 68 (10.0) | 20 (11.9) | 3 (2.1) | 18 (12.4) | 14 (14.1) | 2 (5.6) | 11 (12.5) |
| Mild liver disease | 56 (8.2) | 12 (7.1) | 17 (11.6) | 3 (2.1) | 8 (8.1) | 7 (19.4) | 9 (10.2) |
| Peripheral vascular disease | 39 (5.7) | 15 (8.9) | 9 (6.2) | 2 (1.4) | 10 (10.1) | 0 (0.0) | 3 (3.4) |
| Myocardial infarction | 37 (5.4) | 8 (4.8) | 13 (8.9) | 9 (6.2) | 5 (5.1) | 0 (0.0) | 2 (2.3) |
| Renal disease | 34 (5.0) | 7 (4.2) | 7 (4.8) | 6 (4.1) | 8 (8.1) | 2 (5.6) | 4 (4.6) |
| Charlson Comorbidity Index | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Mean (SD) | 2.7 (1.3) | 2.6 (1.1) | 3.0 (1.6) | 2.7 (1.3) | 2.7 (1.3) | 2.8 (1.2) | 2.5 (1.1) |
| Median (IQR) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–4) | 2 (2–3) |
| Current active treatment regimen, n (%) | 682 | 168 | 146 | 145 | 99 | 36 | 88 |
| Anti-angiogenic based | 22 (3.2) | 0 (0.0) | 11 (7.5) | 0 (0.0) | 4 (4.0) | 1 (2.8) | 6 (6.8) |
| Mono chemotherapy | 37 (5.4) | 6 (3.6) | 1 (0.7) | 5 (3.5) | 9 (9.1) | 11 (30.6) | 5 (5.7) |
| Dual chemotherapy | 350 (51.3) | 111 (66.1) | 50 (34.3) | 66 (45.5) | 57 (57.6) | 21 (58.3) | 45 (51.1) |
| Triple chemotherapy | 238 (34.9) | 48 (28.6) | 82 (56.2) | 74 (51.0) | 11 (11.1) | 1 (2.8) | 22 (25.0) |
| Anti-HER2 based | 9 (1.3) | 2 (1.2) | 2 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (5.8) |
| Anti-PD1 IO | 26 (3.8) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 18 (18.2) | 2 (5.6) | 5 (5.7) |
EAC Esophageal adenocarcinoma, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, PD1 IO Programmed cell death protein 1 immuno-oncology, SD Standard deviation, UK United Kingdom, US United States